X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs VENUS REMEDIES - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH VENUS REMEDIES PANACEA BIOTECH/
VENUS REMEDIES
 
P/E (TTM) x 22.9 -531.8 - View Chart
P/BV x 3.1 0.2 2,044.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   VENUS REMEDIES
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
VENUS REMEDIES
Mar-17
PANACEA BIOTECH/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs149143 104.1%   
Low Rs8265 126.6%   
Sales per share (Unadj.) Rs84.1324.2 26.0%  
Earnings per share (Unadj.) Rs-18.36.4 -285.6%  
Cash flow per share (Unadj.) Rs-6.740.6 -16.5%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7366.0 22.9%  
Shares outstanding (eoy) m61.2512.34 496.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.40.3 428.3%   
Avg P/E ratio x-6.316.2 -38.9%  
P/CF ratio (eoy) x-17.22.6 -673.3%  
Price / Book Value ratio x1.40.3 486.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,282 551.8%   
No. of employees `0002.80.9 304.5%   
Total wages/salary Rs m1,449251 577.4%   
Avg. sales/employee Rs Th1,874.14,430.1 42.3%   
Avg. wages/employee Rs Th527.0278.0 189.6%   
Avg. net profit/employee Rs Th-407.787.6 -465.5%   
INCOME DATA
Net Sales Rs m5,1544,000 128.8%  
Other income Rs m10023 439.6%   
Total revenues Rs m5,2544,023 130.6%   
Gross profit Rs m-766785 -97.7%  
Depreciation Rs m711422 168.6%   
Interest Rs m1,503344 437.3%   
Profit before tax Rs m-2,88142 -6,842.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m17-37 -45.4%   
Profit after tax Rs m-1,12179 -1,417.6%  
Gross profit margin %-14.919.6 -75.8%  
Effective tax rate %-0.6-87.9 0.7%   
Net profit margin %-21.82.0 -1,100.3%  
BALANCE SHEET DATA
Current assets Rs m3,8102,606 146.2%   
Current liabilities Rs m8,3651,980 422.4%   
Net working cap to sales %-88.415.6 -564.9%  
Current ratio x0.51.3 34.6%  
Inventory Days Days156128 121.4%  
Debtors Days Days6743 155.8%  
Net fixed assets Rs m14,4805,353 270.5%   
Share capital Rs m61123 49.7%   
"Free" reserves Rs m9034,393 20.6%   
Net worth Rs m5,1274,516 113.5%   
Long term debt Rs m5,8321,618 360.4%   
Total assets Rs m19,4338,291 234.4%  
Interest coverage x-0.91.1 -81.6%   
Debt to equity ratio x1.10.4 317.4%  
Sales to assets ratio x0.30.5 55.0%   
Return on assets %2.05.1 38.5%  
Return on equity %-21.91.8 -1,248.6%  
Return on capital %3.66.3 57.8%  
Exports to sales %24.50-   
Imports to sales %10.218.4 55.3%   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525736 71.3%   
Fx inflow Rs m1,5390-   
Fx outflow Rs m942736 127.9%   
Net fx Rs m597-736 -81.1%   
CASH FLOW
From Operations Rs m599997 60.1%  
From Investments Rs m-438-461 94.9%  
From Financial Activity Rs m-303-571 53.0%  
Net Cashflow Rs m-141-35 402.6%  

Share Holding

Indian Promoters % 74.5 32.9 226.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 0.2 333.3%  
FIIs % 1.3 0.6 224.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 66.4 35.5%  
Shareholders   10,259 20,121 51.0%  
Pledged promoter(s) holding % 35.1 36.4 96.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Energy and IT Stocks Witness Buying(12:30 pm)

Stock markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the energy sector and IT sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


May 25, 2018 02:01 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS